Why BSX Stock Hands You So Much Cash Right Now

The market is offering a steep discount on this medical device maker, but the price tag comes with a story about slowing growth. Here’s how to read it.

Boston Scientific (BSX), a maker of medical devices, trades around $44 a share. Over the past year, the stock has fallen 58%, with a sharp 32% drop in just the last three months. Yet the business generates a 5.1% annual free cash flow yield. That cash flow yield sits above the 4.1% paid by the median large company in the S&P 500. The market is offering more cash from this business while simultaneously marking down its price. Is this a bargain, or is the market right to price in a breakdown?

How has this business consistently out-earned the market?

This isn’t a one-year fluke. Boston Scientific’s operating margin over the last twelve months was 19.9%, comfortably ahead of the 18.4% S&P 500 median. Its 3-year average margin of 18.5% shows this profitability is durable. The company’s sales have also outpaced the market, with revenue growing 17.4% over the past year, above the median large company’s 7.5% growth.

This cash is generated by a sprawling portfolio of devices used in cardiology, urology, and endoscopy, among other fields. The company has built a machine that consistently converts sales into cash at a higher rate than its average peer. That underlying strength makes the current market price so jarring.

So why did management just cut its full-year forecast?

The offer exists because the machine just sputtered. Management recently reduced its full-year organic revenue growth guidance to a range of 6.5% to 8.0%. The CEO called it a “guide down that we quite think are not proud of,” reflecting “unanticipated headwinds and changing business patterns.” The market’s reaction has been severe, creating what some see as a wide chasm in the stock’s pricing.

The trouble is concentrated in key growth engines. The WATCHMAN heart device, a major driver, grew 19% organically in Q1, but this was “below our expectations.” The Electrophysiology (EP) business is losing more market share to competitors than anticipated. And the Urology division had a “difficult quarter,” with sales growing just 1% organically. This is the business story the market is pricing in: a fear that the cash flow that looks so attractive today is set to shrink.

What number signals if the slowdown is temporary?

Despite the revenue revision, management is holding the line on profitability, guiding for full-year adjusted earnings per share growth of 9% to 11%. They remain “very bullish about ’27 and ’28,” pointing to new product launches and easier comparisons. But that long-term optimism hinges on proving the recent operational issues are merely temporary setbacks. For investors who see opportunity in the sector but prefer a broader approach, a healthcare ETF like XLV offers exposure to many such names.

The first concrete signal of a turnaround will be whether the company can hit the high end of its 5.0% to 7.0% organic revenue growth forecast for the coming quarter.

For more stocks the market has marked down while the cash kept flowing, our Buy the Dip screen runs exactly that screen every day.

Like The Yield? Own The Discipline Behind It

High cash yields are the market’s most honest offer, and also its most loaded one: some are bargains, some are warnings, and telling them apart name by name is real work that never ends.

That is the work the Trefis High Quality (HQ) Portfolio systematizes: about 30 quality businesses screened for the cash generation, margins, and balance-sheet strength that make a yield trustworthy, then sized and re-balanced with discipline. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Enjoy the one you found; own the system that finds them all.